Pooled TRUST-I and TRUST-II Data Affirm Taletrectinib Benefits for Advanced ROS1+ NSCLC
Taletrectinib (AB-106) showed high and durable overall response rates with favorable tolerability in ROS1-positive NSCLC patients, with 88.8% confirmed overall response rate (cORR) in ROS1 TKI-naive patients and 55.8% in pretreated patients, according to an integrated analysis from TRUST-I and TRUST-II studies presented at the 2024 ESMO Congress.
Related Clinical Trials
Reference News
Pooled TRUST-I and TRUST-II Data Affirm Taletrectinib Benefits for Advanced ROS1+ NSCLC
Taletrectinib (AB-106) showed high and durable overall response rates with favorable tolerability in ROS1-positive NSCLC patients, with 88.8% confirmed overall response rate (cORR) in ROS1 TKI-naive patients and 55.8% in pretreated patients, according to an integrated analysis from TRUST-I and TRUST-II studies presented at the 2024 ESMO Congress.